Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market, By Category (Diagnosis and Monitoring (Blood Glucose Monitoring Devices, Other Testing Devices, Software Programs for Diabetes Monitoring, Artificial Pancreas), Therapeutics (Ins

Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market, By Category (Diagnosis and Monitoring (Blood Glucose Monitoring Devices, Other Testing Devices, Software Programs for Diabetes Monitoring, Artificial Pancreas), Therapeutics (Insulin, Insulin Delivery, Oral Hypoglycemic Agents, Cell Therapies)), By Disease Type (Type 2 Diabetes, Type 1 Diabetes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Diabetes devices and drugs (diagnosis, monitoring and therapeutics) consists of diabetes management right from diagnosis, monitoring, till treatment. Diabetes is characterized by high presence of blood glucose, also called blood sugar, in the body. There are three main types of diabetes: type 1, type 2, and gestational diabetes. Oral glucose tolerance testing and hemoglobin A1c (HbA1c) testing are some of the tests used in the diagnosis of the chronic condition. Treatment options include use of insulin, oral hypoglycemic agents, and others.
Restraints of the Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market
Lack of awareness about diabetes diagnostics and treatment, especially in emerging economies, is expected to hinder growth of the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market. Moreover, recall of diabetes drugs is also expected to limit growth of the market.
Key features of the study:
This report provides in-depth analysis of the global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, and Sanofi.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Category:
Diagnosis and Monitoring
Blood Glucose Monitoring Devices
Other Testing Devices
Software Programs for Diabetes Monitoring
Artificial Pancreas
Therapeutics
Insulin
Insulin Delivery
Oral Hypoglycemic Agents
Cell Therapies
Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Disease Type:
Type 2 Diabetes
Type 1 Diabetes
Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Geography:
North America
By Category
Diagnosis and Monitoring
Blood Glucose Monitoring Devices
Other Testing Devices
Software Programs for Diabetes Monitoring
Artificial Pancreas
Therapeutics
Insulin
Insulin Delivery
Oral Hypoglycemic Agents
Cell Therapies
By Disease Type
Type 2 Diabetes
Type 1 Diabetes
By Country:
U.S.
Canada
Europe
By Category
Diagnosis and Monitoring
Blood Glucose Monitoring Devices
Other Testing Devices
Software Programs for Diabetes Monitoring
Artificial Pancreas
Therapeutics
Insulin
Insulin Delivery
Oral Hypoglycemic Agents
Cell Therapies
By Disease Type
Type 2 Diabetes
Type 1 Diabetes
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Category
Diagnosis and Monitoring
Blood Glucose Monitoring Devices
Other Testing Devices
Software Programs for Diabetes Monitoring
Artificial Pancreas
Therapeutics
Insulin
Insulin Delivery
Oral Hypoglycemic Agents
Cell Therapies
By Disease Type
Type 2 Diabetes
Type 1 Diabetes
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Category
Diagnosis and Monitoring
Blood Glucose Monitoring Devices
Other Testing Devices
Software Programs for Diabetes Monitoring
Artificial Pancreas
Therapeutics
Insulin
Insulin Delivery
Oral Hypoglycemic Agents
Cell Therapies
By Disease Type
Type 2 Diabetes
Type 1 Diabetes
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Category
Diagnosis and Monitoring
Blood Glucose Monitoring Devices
Other Testing Devices
Software Programs for Diabetes Monitoring
Artificial Pancreas
Therapeutics
Insulin
Insulin Delivery
Oral Hypoglycemic Agents
Cell Therapies
By Disease Type
Type 2 Diabetes
Type 1 Diabetes
By Country:
GCC
Israel
Rest of Middle East
Africa
By Category
Diagnosis and Monitoring
Blood Glucose Monitoring Devices
Other Testing Devices
Software Programs for Diabetes Monitoring
Artificial Pancreas
Therapeutics
Insulin
Insulin Delivery
Oral Hypoglycemic Agents
Cell Therapies
By Disease Type
Type 2 Diabetes
Type 1 Diabetes
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Abbott Laboratories *
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Bristol-Myers Squibb
DexCom, Inc.
Eli Lilly and Company
Companion Medical
GlaxoSmithKline plc
Glenmark Pharmaceuticals
Johnson & Johnson
Lupin Ltd.
F. Hoffmann-La Roche AG
Sanofi
“*” marked represents similar segmentation in other categories in the respective section.